Trade
Trading Type
Spot
Trade crypto freely
Alpha
Points
Get promising tokens in streamlined on-chain trading
Pre-Market
Trade new tokens before they are officially listed
Margin
Magnify your profit with leverage
Convert & Block Trading
0 Fees
Trade any size with no fees and no slippage
Leveraged Tokens
Get exposure to leveraged positions simply
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
Investment
Simple Earn
VIP
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Quant Fund
VIP
Top asset management team helps you profit without hassle
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-Stop Lending Hub
VIP Wealth Hub
New
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Staking
Stake cryptos to earn in PoS products
BTC Staking
HOT
Stake BTC and earn 10% APR
GUSD Minting
New
Use USDT/USDC to mint GUSD for treasury-level yields
Soft Staking
Earn rewards with flexible staking
More
- Trending TopicsView More
2.4K Popularity
37.6K Popularity
1.9K Popularity
452 Popularity
186.1K Popularity
- Pin
- 📢 Gate Square Ambassador Recruitment is Now Open! 🔥
Join Gate Ambassadors for more than just creating — embark on an exciting journey! 💡
As a Square Ambassador, you’ll enjoy:
🎁 Exclusive perks to showcase your unique value
💰 Square task alerts — earn rewards while posting
🎨 Limited-edition merch — become an official Gate representative
⭐ VIP5 status + Square Yellow V badge — stand out with ease
🚀 Join us and become:
A community influencer
A Web3 creative pioneer
A promoter of quality content
🎉 Click to apply and start your ambassador journey: https://www.gate.com/questionnaire/4937
📖 - Gate App Options Now Live! Test and Win Big
📅 Event Period: September 30, 2025 – October 17, 2025
- Submit valid feedback to receive 10–100 USDT.
- Complete at least 10,000 USDT in cumulative options trading volume to participate.
👉 Register now ：https://www.gate.com/campaigns/2063
Details: https://www.gate.com/zh-tw/announcements/article/47455
The first three common De-Da-Botu monoclonal antibody has been approved in Japan for the treatment of breast cancer.
On December 28, Jinshi Data reported that on December 27, local time, The First Three Company announced that the targeted TROP2 antibody-drug conjugate (ADC) DATROWAY® (trastuzumab deruxtecan) developed by the company in collaboration with AstraZeneca has been approved in Japan for the treatment of adult patients with unresectable or recurrent breast cancer who are hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), and have an immunohistochemistry (IHC) score of 0, 1+, or 2+ with in situ hybridization (ISH-) after receiving chemotherapy.